CBR3

Across TCGA pan-cancer cohorts, CBR3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CBR3 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CBR3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CBR3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where CBR3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.547	0.270	<.001	34	view →
LUAD	OS	Quartile	II,III,IV	0.369	0.868	.010	12	view →
CCRCC	OS	Quartile	All	0.858	1.000	.014	9	view →
LSCC	DFS	Median	III,IV	0.485	0.840	.041	7	view →
HNSC	OS	Median	III,IV	1.000	0.484	.038	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CBR3–PDAC (DFS)

Open the PDAC breakdown →